FBR2 can inhibit ferroptosis and cellular senescence induced by BLM through the SIRT3/p53 pathway, potentially involving alterations in the acetylation of p53, thereby treating pulmonary fibrosis (Figure 10). This evidence concerns the gene TP53 and pulmonary fibrosis.